ArticleJournal of inflammation research2025
Integrating Network Pharmacology and in vivo Validation to Explore the Mechanisms of Buyang Huanwu Decoction in Myocardial Ischemia-Reperfusion Injury.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Comprehensive network pharmacology study on Huangjing Wan in the treatment of ischaemic stroke.Medicine · 2026Article
- Identification of NF-κB pathway-related biomarkers in myocardial ischemia-reperfusion injury: based on transcriptomics analysis and RT-qPCR validation.Scientific reports · 2026Article
- Shenqi Granules Enhance Recovery from Myocardial Ischemia-Reperfusion Injury by Downregulating MMP9 and ADH1C.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Network pharmacology analysis and experimental validation elucidate the protective mechanisms of BYHWD against hypoxia/reoxygenation-induced endothelial cell injury.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Buyang Huanwu Decoction (BYHWD), a traditional Chinese herbal formula, has been widely used to manage cardiovascular disorders. However, its cardioprotective mechanisms in myocardial ischemia/reperfusion injury (MI/RI) remain unclear. This study aims to investigate its pharmacological mechanisms against MI/RI through network pharmacology and experimental validation. Materials and Methods: Active components and targets of BYHWD were identified via Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, Encyclopedia of Traditional Chinese Medicine, BATMAN-TCM, and SymMap databases. MI/RI-related targets were retrieved from DisGeNET, GeneCard, Online Mendelian Inheritance in Man, Comparative Toxicogenomics Database, and DrugBank databases. The intersecting targets were analyzed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment. Protein-protein interaction (PPI) networks, compound-target networks, and herb-target-pathway networks were constructed using Cytoscape, and molecular docking was performed via AutoDock Vina. A rat MI/RI model was used to assess infarct size, protein expression, and cytokine levels for in vivo validation. Results: 95 compounds were identified, with 75 MI/RI-related targets. PPI analyses highlighted ten hub genes, including interleukin-6 (IL6), AKT serine/threonine kinase 1 (AKT1), tumor necrosis factor (TNF), intercellular adhesion molecule 1 (ICAM1), matrix metalloproteinase 9 (MMP9), interleukin-10 (IL10), vascular cell adhesion molecule 1 (VCAM1), nitric oxide synthase 3, albumin, and C-reactive protein. GO and KEGG analyses highlighted TNF signaling, apoptosis, and p53 signaling pathways. Conclusion: BYHWD alleviates MI/RI through multicomponent, multitarget, and multipathway mechanisms, primarily modulating TNF and AKT1-mediated inflammatory/apoptotic pathways. These effects collectively support its potential as a complementary treatment for ischemic heart disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.